Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Trial of BMS-599626 (AC480), an Oral Pan-HER Receptor Tyrosine Kinase Inhibitor, in Patients with Advanced Solid Tumors

Author(s): Jean-Charles Soria, Javier Cortés, Christophe Massard, Jean-Pierre Armand, Desiree De Andreis, Stanislas Ropert, Eva López, Aurélie Catteau, Joyce James, Jean-Francois Marier, Martin Beliveau, Robert Martell, José Baselga
Year: February 1, 2012
Learn More LinkedIn Twitter Facebook Email